Recent biotech deals involving reverse mergers and BTK inhibitors advancing in immune and inflammatory (I&I) disease programs include Processa Pharmaceuticals' acquisition of Vidya Therapeutics via an all‑stock reverse‑merger style transaction, and Caldera Therapeutics’ reverse merger with Synlogic to advance its IBD‑focused pipeline.
Processa’s deal centers on a differentiated clinical‑stage BTK inhibitor with broad potential in immune‑mediated disorders, supported by a $200 million private placement that gives the combined company a multi‑year runway; prior to the merger, Processa itself had gone public in 2017 via a reverse merger with an asphalt‑equipment company.
Caldera Therapeutics, an inflammatory bowel disease (IBD) startup, struck a reverse merger with Nasdaq‑listed Synlogic, valuing the combined company at roughly $500 million and including a $278 million private placement to fund its IBD pipeline development.
Separately, Travere Therapeutics has licensed the covalent reversible BTK inhibitor civorebrutinib from Everest Medicines for up to $1.14 billion to treat rare and immune‑mediated kidney diseases, while other companies such as Zenas BioPharma and Nurix Therapeutics have advanced BTK‑targeted programs into immunology and neurology indications through licensing and collaboration deals.
Sources:
Processa Acquisition Lands Immunology Drug That Could ...
Caldera hits Nasdaq via Synlogic reverse merger
Two Biotech Catalysts, One Week, and What Institutional ...
Travere buys BTK inhibitor for $1.1bn to treat kidney disease
Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics
Beigene moves BTK inhibitor into the clinic, inks manufacturing deal with BI
RTW Biotech rises as cancer therapy firm agrees to reverse ...
Travere beefs up rare kidney disease portfolio with up to ...
PCSA: Stock-for-stock acquisition and $200M PIPE create a BTK-focused biotech with runway into 2029
Boston biotech opts for reverse merger with San Diego company